1. INTRODUCTION
===============

Lung cancer is a rising epidemic and remains the leading cause of cancer death in both men and women in Canada[@b1-co16-2-16]. In general, 500 Canadians are diagnosed with and 400 Canadians die of lung cancer every week[@b1-co16-2-16]. Such high morbidity and mortality in patients with primary lung cancer emphasizes the need for palliative treatment intent.

Morbidity from lung cancer or lung metastases often presents as troublesome thoracic symptoms such as hemoptysis, cough, chest pain, and dyspnea. Palliative radiotherapy has been effective in ameliorating these symptoms [@b2-co16-2-16]--[@b4-co16-2-16] and improves or preserves the quality of life ([qol]{.smallcaps}) remaining in approximately one third of affected patients[@b5-co16-2-16].

In the past, clinical trials in patients with lung cancer have focused on traditional endpoints such as overall survival, disease-free survival, or local control [@b6-co16-2-16]. Given the relatively poor prognosis of patients with locally advanced lung cancer or lung metastases, the inclusion of [qol]{.smallcaps} as a primary endpoint of treatment becomes increasingly important. Quality of life encompasses the minimization of risks and maximization of benefits of a treatment, including physical and psychosocial effects on the well-being of patients[@b7-co16-2-16]. Studying [qol]{.smallcaps} is particularly relevant in the field of palliative radiotherapy because of known treatment-related side effects and toxicities.

Few studies focus on [qol]{.smallcaps} and symptom palliation as primary endpoints. The purpose of the present review was to accurately assess the recent use of [qol]{.smallcaps} tools in trials that evaluated the efficacy of palliative radiotherapy in patients with lung cancer or lung metastases.

2. METHODS
==========

2.1 Search Strategy
-------------------

We conducted a literature review using the [medline]{.smallcaps} (Ovid) database for 1950 to February 2008. Key terms such as "lung cancer," "lung neoplasms," or "lung metastases" were combined with the terms "radiotherapy," "radiation," "external-beam irradiation," or "palliative radiotherapy." This search was then combined with "quality of life" or "[qol]{.smallcaps}" and also "symptom palliation." Relevant articles and abstracts were reviewed, and references from those sources were also manually searched for additional relevant publications.

2.2 Inclusion Criteria
----------------------

To be included in the present literature review, articles had to meet these criteria:

-   Population: patients with a histologic, cytologic, or radiologic diagnosis of primary lung cancer or lung metastases

-   Intervention: external beam radiotherapy or endobronchial brachytherapy in at least one study arm, with palliative intent

-   Types of studies: randomized trials, prospective or retrospective cohort studies

-   Endpoints: [qol]{.smallcaps} or symptom palliation as a primary or secondary endpoint or measured outcome

2.3 Exclusion Criteria
----------------------

Articles were excluded if they met any of these criteria:

-   Article type: individual case report or review article

-   Language: publication in a language other than English

-   Intervention: no evaluation, in at least one arm, of external beam irradiation to the thorax or endobronchial brachytherapy; or studies of interventions with curative intent

-   Types of studies: focus on populations other than those with primary lung cancer or lung metastases

-   Endpoints: use of the Karnofsky performance status ([kps]{.smallcaps}) or other similar prognostic tools, correlation of [qol]{.smallcaps} with cost--utility, or test of the reliability or validity of a [qol]{.smallcaps} instrument

2.4 Data Extraction
-------------------

We extracted the following information from the studies:

-   Primary and secondary outcomes

-   Radiotherapy treatment details

-   Type and number of [qol]{.smallcaps}, symptom palliation, and additional tools, if any, used

-   Number of patients in each study arm

-   Median age and male: female ratio of the patients enrolled in the study

-   Median survival in each study arm

3. RESULTS
==========

We identified a total of forty-three trials that evaluated, in at least one study arm, the use of palliative radiotherapy to the thorax, and that assessed [qol]{.smallcaps} or symptom palliation as a primary or secondary endpoint. Thirty studies ([Table I](#tI-co16-2-16){ref-type="table"}) evaluated the treatment of patients with non-small-cell lung cancer ([nsclc]{.smallcaps}). Four studies ([Table II](#tII-co16-2-16){ref-type="table"}) involved patients who were treated with endobronchial brachytherapy alone or in addition to external-beam radiation. Brachytherapy differs from external-beam radiation in that it is a more localized form of radiation that limits toxicity in healthy tissue to the immediate vicinity of the radiated region[@b5-co16-2-16]. Another nine trials ([Table III](#tIII-co16-2-16){ref-type="table"}) evaluated the use of palliative radiotherapy in patients with lung cancer of a histologic type other than [nsclc]{.smallcaps}. The four identified studies that measured the difference in efficacy between endobronchial brachytherapy and external beam radiation [@b37-co16-2-16]--[@b40-co16-2-16] used both symptom palliation and [qol]{.smallcaps} scores as a primary outcome.

In twenty of the identified studies, symptom palliation was used as a primary outcome [@b8-co16-2-16],[@b10-co16-2-16],[@b11-co16-2-16],[@b13-co16-2-16], [@b14-co16-2-16],[@b17-co16-2-16],[@b19-co16-2-16],[@b20-co16-2-16],[@b21-co16-2-16],[@b23-co16-2-16],[@b26-co16-2-16],[@b28-co16-2-16]--[@b33-co16-2-16],[@b44-co16-2-16],[@b45-co16-2-16],[@b47-co16-2-16]. Ten trials used [qol]{.smallcaps} as a primary outcome [@b5-co16-2-16],[@b9-co16-2-16],[@b16-co16-2-16],[@b18-co16-2-16],[@b24-co16-2-16],[@b25-co16-2-16],[@b34-co16-2-16],[@b35-co16-2-16],[@b39-co16-2-16],[@b49-co16-2-16], and six studies used both symptom palliation and [qol]{.smallcaps} together as a primary endpoint [@b22-co16-2-16],[@b27-co16-2-16],[@b37-co16-2-16],[@b38-co16-2-16],[@b40-co16-2-16],[@b48-co16-2-16]. Seven of the studies used neither symptom palliation nor [qol]{.smallcaps} as primary endpoints, but rather incorporated them as secondary outcomes [@b12-co16-2-16],[@b15-co16-2-16],[@b36-co16-2-16],[@b41-co16-2-16]--[@b43-co16-2-16],[@b46-co16-2-16]. The four identified studies that measured the difference in efficacy between endobronchial brachytherapy and external beam radiation[@b37-co16-2-16]--[@b40-co16-2-16] used both symptom palliation and [qol]{.smallcaps} scores as primary outcomes.

3.1 QOL and Symptom Palliation Tools Used
-----------------------------------------

A total of 11 tools were used to assess either [qol]{.smallcaps} or palliation of lung cancer--related symptoms; the frequency of use of each tool is presented in [Table IV](#tIV-co16-2-16){ref-type="table"}. The most common [qol]{.smallcaps} tool used was the European Organization for Research and Treatment of Cancer ([eortc]{.smallcaps}) [qlq]{.smallcaps}-C30, a questionnaire that was created and validated to assess [qol]{.smallcaps} in individuals with any form of cancer. It has been translated into 81 languages and consists of 30 questions that encompass 5 functional scales: physical, role, cognitive, emotional, and social functioning[@b49-co16-2-16]. The [eortc qlq]{.smallcaps}-C30 also incorporates 3 symptom scales: fatigue, pain, and nausea and vomiting. The remaining items on the questionnaire cover other symptom-related events that are often described by cancer patients, including dyspnea, diarrhea, and loss of appetite, among others[@b48-co16-2-16].

The [eortc qlq]{.smallcaps}-C30 was used in fourteen of the forty-three studies identified in the search (32%), eight of which also used the lung cancer supplement, [eortc qlq]{.smallcaps}-LC13. The [eortc qlq]{.smallcaps}-LC13 is the latest version of a lung cancer specific questionnaire that consists of questions concerning lung cancer symptoms and the side effects of conventional treatments used for lung cancer[@b49-co16-2-16]. One trial used an older version of the lung-specific module, the [eortc qlq]{.smallcaps}-LC17, in addition to the general questionnaire[@b48-co16-2-16]

The Functional Assessment of Cancer Therapy ([fact]{.smallcaps}) [qol]{.smallcaps} tools constituted a second group used in the identified studies. Both the general questionnaire ([fact]{.smallcaps}-G) and the lung-specific questionnaire ([fact]{.smallcaps}-L) were used. Like the [eortc qlq]{.smallcaps}-C30, the [fact]{.smallcaps}-G is a general questionnaire that was developed for pa­tients with any type of cancer. The [fact]{.smallcaps}-G covers 4 dimensions of [qol]{.smallcaps}: physical, social, emotional, and functional well-being[@b50-co16-2-16]. The [fact]{.smallcaps}-L is similar to the [eortc qlq]{.smallcaps}-LC13 because it includes additional ques­tions that relate specifically to [qol]{.smallcaps} in patients with lung cancer. The [fact]{.smallcaps}-L was used in two studies, and the [fact]{.smallcaps}-G in one.

A third validated [qol]{.smallcaps} tool was used in one trial: the Spitzer [qol]{.smallcaps} Index. The Spitzer Index covers 5 dimensions of [qol]{.smallcaps}: activity, daily living, health, support of family and friends, and outlook[@b51-co16-2-16]. It is not a lung cancer--specific questionnaire, however; and thus it does not incorporate questions directly related to the lung-cancer-specific patient population.

Study-designed questionnaires were the most prevalent tool used in the forty-three identified stud­ies. A study-specific method of determining [qol]{.smallcaps} was used in three trials, and nineteen trials attempted to evaluate symptom palliation using a study-designed questionnaire. [Table V](#tV-co16-2-16){ref-type="table"} shows a breakdown of the proportion of studies using a validated [qol]{.smallcaps} or symptom palliation tool as compared with a study-designed tool. Study-designed instruments present a difficulty: drawing comparisons across studies is harder because the methods of measurement vary.

In five studies, a validated symptom palliation tool was used (the frequency of use can be seen in [Table IV](#tIV-co16-2-16){ref-type="table"}). The two general symptom tools used were the Hospital Anxiety and Depression Scale and the Rotterdam Symptom Checklist. The Rotterdam Symptom Checklist measures psychological and physical distress in cancer patients through the use of 38 items[@b52-co16-2-16]. The Hospital Anxiety and Depression Scale is a tool used to measure anxiety and depression levels using 14 statements based on a patient's experience over the preceding week[@b53-co16-2-16]. One lung-specific symptom tool the Lung Cancer Symptom Scale was used. The Lung Cancer Symptom Scale is a tool designed to measure 6 lung-specific symptoms and their effects on symptomatic distress, functional burden, and global quality of life[@b54-co16-2-16],[@b55-co16-2-16].

[Figure 1](#f1-co16-2-16){ref-type="fig"} outlines the overall picture of questionnaire use in the identified trials. Most of the trials (54%) measured symptom palliation alone; some measured both symptom palliation and [qol]{.smallcaps} (14%). The remaining trials measured [qol]{.smallcaps} only.

3.2 Performance Assessment
--------------------------

In forty studies (91%), the performance status of the subjects was measured in addition to [qol]{.smallcaps} or symptom palliation. Performance status was measured primarily as a prognostic factor (twenty of forty trials, 50%) or as part of the exclusion criteria (fourteen of forty trials, 35%). Only six studies used a performance scale as part of the assessment. The 3 most predominant performance status tools used were the World Health Organization performance status, the Eastern Cooperative Oncology Group scale, and the Karnofsky performance status ([kps]{.smallcaps}). Although performance scales are useful to determine the functional status of a patient, they are not adequate tools for measuring symptom palliation or [qol]{.smallcaps}.

4. DISCUSSION
=============

In patients with terminal cancer, [qol]{.smallcaps} is a significant concept, and it is influencedby many factors, including symptoms, functional level, coping strategies, and support systems[@b51-co16-2-16]. Common symptoms that influence a lung cancer patient's [qol]{.smallcaps} include anxiety, depression, pain, fatigue, dyspnea, and cough[@b52-co16-2-16]. Because lung cancer is the leading cause of cancer death in men and the second-leading cause in women globally[@b2-co16-2-16], it is important that [qol]{.smallcaps} is considered when caring for these patients.

Meaningful palliation refers to symptom relief and prolongation of good-quality survival in lung cancer patients[@b26-co16-2-16]. When treating a patient with palliative intent, it is necessary to use tools that measure the intent of the treatment. For 86% of doctors from the United Kingdom, the United States, and Canada, the treatment of choice for patients with inoperable report of a lung cancer is palliative radiotherapy[@b33-co16-2-16]. It is therefore important that, when considering the side effects of palliative radiotherapy as compared with the side effects of the lung cancer itself, trials investigating the use of palliative radiotherapy use a [qol]{.smallcaps} measure to determine the benefit of the treatment.

A total of twenty identified trials considering palliative radiotherapy for lung cancer included an evaluation of [qol]{.smallcaps}. Of these trials, eleven used a tool that was specific to patients with lung cancer; the remaining nine used general [qol]{.smallcaps} questionnaires for cancer patients or a study-designed questionnaire. In thirty-one identified studies, the level of symptom palliation, one aspect that contributes to a [qol]{.smallcaps} measure, was assessed. This finding suggests that more trials should use a validated lung-specific tool when evaluating the outcome of palliative thoracic radiotherapy. Use of a validated, lung-specific tool will allow for comparisons between trials and will also increase the internal validity of individual studies. Two recommended lung-specific validated tools that would be beneficial for the measurement of [qol]{.smallcaps} in trials evaluating palliative thoracic radiotherapy are the [fact]{.smallcaps}-L and the [eortc qlq]{.smallcaps}-LC13.
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###### 

Patients with inoperable non-small-cell lung cancer ([nsclc]{.smallcaps}) treated with palliative radiotherapy

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                            Type                              Study Purpose                                                                                                                                                                     Arms                                                                                                                    Pts (*n*)   Median survival               [qol]{.smallcaps}                                                                                  Assessment tools Performance            Other                                                                                                                  Measures of [qol]{.smallcaps} (*n*)
  -------------------------------------------------------------------- --------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------- ----------------------------- -------------------------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -------------------------------------
  Simpson *et al.*, 1985 [@b8-co16-2-16]                               [rct]{.smallcaps} (multicentre)   To evaluate 3 [xrt]{.smallcaps} schedules and determine the most efficient                                                                                                        A: 40 Gy split course in 4 weeks\                                                                                       316         A: 6.2 months\                None                                                                                               [kps]{.smallcaps}                       Study designed: self-report either complete relief or relative relief by patient                                       0
                                                                                                                                                                                                                                                                                           B: 30 Gy continuous for 2 weeks\                                                                                                    B: 6.4 months\                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                           C: 40 Gy continuous for 4 weeks                                                                                                     C: 6.9 months                                                                                                                                                                                                                                                                                   

  Kaasa *et al.*, 1988 [@b9-co16-2-16]                                 [rct]{.smallcaps}                 [qol]{.smallcaps} of patients with radiation therapy and chemotherapy                                                                                                             A: Combination chemotherapy\                                                                                            95          Not stated                    Study designed: 29 variables; only psychosocial well-being and global [qol]{.smallcaps} reported   [who]{.smallcaps}                       None                                                                                                                   0
                                                                                                                                                                                                                                                                                           B: 42 Gy/15 fr                                                                                                                                                                                                                                                                                                                                                                                                                      

  Teo *et al.*, 1988 [@b10-co16-2-16]                                  [rct]{.smallcaps}                 To compare a hypofractionated scheme with traditional fractionation                                                                                                               A: 45 Gy/18 fr\                                                                                                         291         Not stated                    None                                                                                               [kps]{.smallcaps}                       Study designed: subjective responses in thoracic symptoms to changes                                                   0
                                                                                                                                                                                                                                                                                           B: 31.2 Gy/4 fr                                                                                                                                                                                                                                                                                                                                                                                                                     

  [mrc]{.smallcaps} Lung Cancer Working Party, 1991 [@b11-co16-2-16]   Randomized prospective            To determine if a shorter treatment course of [xrt]{.smallcaps} provides equally good symptom palliation                                                                          A: 17 Gy/2 fr\                                                                                                          369         A: 179 days\                  None                                                                                               [who]{.smallcaps}                       Study designed: 4-point scale to rate symptoms                                                                         0
                                                                                                                                                                                                                                                                                           B: 30 Gy/10 fr                                                                                                                      B: 177 days                                                                                                                                                                                                                                                                                     

  Regan *et al.*, 1991 [@b12-co16-2-16]                                Prospective                       Correlate physician rating of [xrt]{.smallcaps} response to patient views of treatment                                                                                            A: 30 Gy/10 fr\                                                                                                         40          30 Days                       [eortc qlq]{.smallcaps}-C30                                                                        [ecog]{.smallcaps}                      [mrc]{.smallcaps} physician questionnaire                                                                              1
                                                                                                                                                                                                                                                                                           B: 17 Gy/2 fr                                                                                                                                                                                                                                                                                                                                                                                                                       

  [mrc]{.smallcaps} Lung Cancer Working Party, 1992 [@b13-co16-2-16]   [rct]{.smallcaps}                 Investigate whether a single fraction can provide palliation as good as that provided by 2 fractions                                                                              A: 17 Gy/2 fr\                                                                                                          233         A: 100 days\                  None                                                                                               [who]{.smallcaps}                       Study designed: daily dairy for first 6 months: 4-point scale to rate symptoms                                         0
                                                                                                                                                                                                                                                                                           B: 10 Gy/1 fr                                                                                                                       B: 122 days                                                                                                                                                                                                                                                                                     

  Omand and Meredith, 1994 [@b14-co16-2-16]                            Prospective                       To assess frequency of acute side effects of short-term [xrt]{.smallcaps}                                                                                                         A: 10 Gy/1 fr\                                                                                                          61          Not stated                    None                                                                                               None                                    Study designed: percentage improvement in symptoms                                                                     0
                                                                                                                                                                                                                                                                                           B: 17Gy/ 2 fr                                                                                                                                                                                                                                                                                                                                                                                                                       

  Abratt *et al.*, 1995 [@b15-co16-2-16]                               Randomized prospective            To evaluate the dose--response effect on survival of patients with good performance status                                                                                        A: 35 Gy/10 fr\                                                                                                         84          A: 8.5 months\                None                                                                                               [who]{.smallcaps}                       Study designed: physician graded symptom improvements                                                                  0
                                                                                                                                                                                                                                                                                           B: 45 Gy/15 fr                                                                                                                      B: 8.5 months                                                                                                                                                                                                                                                                                   

  Macbeth *et al.*, 1996[@b16-co16-2-16]                               Randomized (multicentre)          To compare palliative with more-intensive [xrt]{.smallcaps} with respect to survival and [qol]{.smallcaps}                                                                        A: 17 Gy/2 fr\                                                                                                          509         A: 7 months\                  None                                                                                               [who]{.smallcaps}                       [hads, rscl mrc]{.smallcaps} patient diary card                                                                        0
                                                                                                                                                                                                                                                                                           B: 39 Gy/13 fr                                                                                                                      B: 9 months                                                                                                                                                                                                                                                                                     

  Ball *et al.*, 1997[@b17-co16-2-16]                                  Prospective                       To assess the effect of adding continuous-infusion fluorouracil to palliative [xrt]{.smallcaps}                                                                                   A: 20 Gy/5 fr\                                                                                                          200         A: 6 months\                  Study-designed questionnaire                                                                       [who]{.smallcaps}                       Study-designed questionnaire to detect symptom palliation                                                              1
                                                                                                                                                                                                                                                                                           B: 20 Gy/5 fr with fluorouracil for 5 days                                                                                          B: 6.8 months                                                                                                                                                                                                                                                                                   

  Gava *et al.*, 1997[@b18-co16-2-16]                                  Prospective (multicentre)         To assess the indications for [xrt]{.smallcaps}, compliance with treatment plans, and [qol]{.smallcaps}                                                                           A: Radical range: 30Gy--70Gy\                                                                                           A: 109\     Not stated                    Study designed                                                                                     [kps]{.smallcaps}                       None                                                                                                                   
                                                                                                                                                                                                                                                                                           B: Palliative range: \<30 Gy to 70 Gy                                                                                   B: 73                                                                                                                                                                                                                                                                                                       

  Lutz *et al.*, 1997[@b19-co16-2-16]                                  Retrospective                     To measure symptom palliation in patients treated with [xrt]{.smallcaps}                                                                                                          30 Gy/10--12 fr                                                                                                         54          4 Months                      None                                                                                               [swog]{.smallcaps} performance status   [lcss]{.smallcaps}                                                                                                     1

  Vyas *et al.*, 1998[@b20-co16-2-16]                                  Retrospective                     To evaluate response in patients receiving palliative [xrt]{.smallcaps} in 2 large fractions                                                                                      17 Gy/2 fr                                                                                                              37          Not stated                    None                                                                                               Not stated                              Study designed: patients asked to grade percentage improvement in symptoms                                             0

  Donato *et al.*, 1999 [@b21-co16-2-16]                               Prospective                       To examine the results obtained with a fractionated [rt]{.smallcaps} regimen                                                                                                      A: 20 Gy/5 fr (1 treatment)\                                                                                            52          Not stated                    None                                                                                               [ecog, kps]{.smallcaps}                 Study designed: subjective patient assessment of symptoms                                                              0
                                                                                                                                                                                                                                                                                           B: 40 Gy/10 (2 treatments)                                                                                                                                                                                                                                                                                                                                                                                                          

  Langendijk *et al.*, 2000 [@b5-co16-2-16]                            Prospective                       To see the association between prognostic factors and [qol]{.smallcaps} and the impact of symptoms on [qol]{.smallcaps}                                                           A: Curative schedule: 70 Gy in 7 weeks B: Radical schedule: 60 Gy in 6 weeks C: Palliative schedule: 30 Gy in 4 weeks   262         A: 19.1 months\               [eortc]{.smallcaps}-[qlq]{.smallcaps}-C30\                                                         [who]{.smallcaps}                       None                                                                                                                   2
                                                                                                                                                                                                                                                                                                                                                                                                                               B: 8.5 months C: 4.1 months   [eortc qlq]{.smallcaps}-LC13                                                                                                                                                                                                                                      

  Langendijk *et al.*, 2000 [@b22-co16-2-16]                           Prospective                       To investigate changes in symptoms and [qol]{.smallcaps} in patients receiving [xrt]{.smallcaps}                                                                                  30 Gy/in 4 weeks                                                                                                        65          Not stated                    [eortc qlq]{.smallcaps}-C30\                                                                       who                                     None                                                                                                                   2
                                                                                                                                                                                                                                                                                                                                                                                                                                                             [eortc qlq]{.smallcaps}-LC13                                                                                                                                                                                                                                      

  Nestle *et al.*, 2000 [@b23-co16-2-16]                               Randomized prospective            To see if there is a difference between palliative and more intensive treatment                                                                                                   A: 60 Gy/30 fr\                                                                                                         152         A: 8.3 months\                None                                                                                               [kps]{.smallcaps}                       Study designed: [mrc]{.smallcaps} daily diary card                                                                     0
                                                                                                                                                                                                                                                                                           B: 32 Gy/20 fr                                                                                                                      B: 8.4 months                                                                                                                                                                                                                                                                                   

  Schaafsma and Coy, 2000 [@b24-co16-2-16]                             Prospective                       To estimate the effect of high-dose [xrt]{.smallcaps} on [qol]{.smallcaps} and computer [qald]{.smallcaps} gained                                                                 30 Gy/10 fr                                                                                                             54          266 Days                      [eortc qlq]{.smallcaps}-C30                                                                        [kps]{.smallcaps}                       None                                                                                                                   1

  Auchter *et al.*, 2001 [@b25-co16-2-16]                              Prospective                       To evaluate [qol]{.smallcaps} of patients before, at completion, and after accelerated fractionation of [xrt]{.smallcaps}                                                         57.6 Gy/36 fr over 15 days                                                                                              30          13 Months                     [fact]{.smallcaps}-L                                                                               [ecog]{.smallcaps}                      None                                                                                                                   1

  BCentingoz *et al.* , 2001 [@b26-co16-2-16]                          Retrospective                     To retrospectively evaluate the treatment effects of [xrt]{.smallcaps}                                                                                                            Median dose: 30 Gy/1--23 fr                                                                                             115         30 Weeks                      None                                                                                               [kps]{.smallcaps}                       Study designed: subjective palliation rates in one of three groups: near total response, improvement, or no response   0

  Langendijk *et al.*, 2001 [@b27-co16-2-16]                           Prospective                       To evaluate changes in [qol]{.smallcaps} and symptoms after [xrt]{.smallcaps}                                                                                                     60 Gy total dose                                                                                                        164         8.5 Months                    [eortc qlq]{.smallcaps}-C30\                                                                       [who]{.smallcaps}                       None                                                                                                                   2
                                                                                                                                                                                                                                                                                                                                                                                                                                                             [eortc qlq]{.smallcaps}-LC13                                                                                                                                                                                                                                      

  Bejzak *et al.*, 2002 [@b28-co16-2-16]                               [rct]{.smallcaps} (multicentre)   Comparison of 2 fractionation schedules on palliation of symptoms                                                                                                                 A: 10 Gy/1 fr\                                                                                                          230         A: 4.2 months\                [eortc qlq]{.smallcaps}-C30                                                                        [ecog]{.smallcaps}                      [lcss]{.smallcaps} (1 item)                                                                                            1
                                                                                                                                                                                                                                                                                           B: 20 Gy/5 fr                                                                                                                       B: 6 months                                                                                                                                                                                                                                                                                     

  Falk et al., 2002 29                                                 [rct]{.smallcaps} (multicentre)   To determine if patients should be given palliative [xrt]{.smallcaps} immediately or as needed for symptom relief                                                                 A: 17 Gy/2 fr\                                                                                                          230         A: 240 days\                  None                                                                                               [who]{.smallcaps}                       [hads]{.smallcaps}, [rscl]{.smallcaps}                                                                                 0
                                                                                                                                                                                                                                                                                           B: 10 Gy/1 fr                                                                                                                       B: 253 days                                                                                                                                                                                                                                                                                     

  Nihei *et al.*, 2002 [@b30-co16-2-16]                                Retrospective                     To investigate the outcome of [xrt]{.smallcaps} for airway stenosis                                                                                                               30 Gy/10 fr                                                                                                             24          Responders: 192 days\         None                                                                                               None                                    Study designed:\                                                                                                       0
                                                                                                                                                                                                                                                                                                                                                                                                                               Non-responders: 43 days                                                                                                                                                  Patient subjective report of symptoms                                                                                  

  Borthwick *et al.*, 2003 [@b31-co16-2-16]                            Prospective                       To gain an understanding of fatigue in patients receiving [xrt]{.smallcaps}                                                                                                       A: Radical:\                                                                                                            53          Not stated                    None                                                                                               Not stated                              Study designed: daily card with 9 questions relating to fatigue                                                        0
                                                                                                                                                                                                                                                                                           55 Gy/20 fr\                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                           B: Palliative:\                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                           39 Gy/13 fr                                                                                                                                                                                                                                                                                                                                                                                                                         

  Kramer *et al.*, 2005 [@b32-co16-2-16]                               [rct]{.smallcaps} (multicentre)   Compare various fractions of [xrt]{.smallcaps} on palliation of thoracic symptoms                                                                                                 A: 16 GY/2 fr\                                                                                                          297         Not stated                    None                                                                                               [ecog]{.smallcaps}                      [rscl]{.smallcaps}                                                                                                     0
                                                                                                                                                                                                                                                                                           B: 30 GY/10 fr                                                                                                                                                                                                                                                                                                                                                                                                                      

  Senkus--Konefka *et al.*, 2005 [@b33-co16-2-16]                      Randomized prospective            To compare two palliative [xrt]{.smallcaps} schedules                                                                                                                             A: 20 Gy/5 fr\                                                                                                          100         A: 5.3 months\                None                                                                                               [who]{.smallcaps}                       Study designed: patient-reported symptom relief on a 4-point scale                                                     0
                                                                                                                                                                                                                                                                                           B: 16 Gy/2 fr                                                                                                                       B: 8.0 months                                                                                                                                                                                                                                                                                   

  Sundstrøm *et al.*, 2005 [@b34-co16-2-16]                            Randomized prospective            To compare the course of symptoms and [hr qol]{.smallcaps} after immediate thoracic [rt]{.smallcaps} between symptomatic (Sym) and non-Sym (NSym) patients                        17 Gy/2 fr\                                                                                                             395         NSym: 11.8 months\            [eortc qlq]{.smallcaps}-C30\                                                                       [kps]{.smallcaps}                       None                                                                                                                   2
                                                                                                                                                                                                                                                                                           42 Gy/15 fr\                                                                                                                        Sym: 6.0 months               [eortc qlq]{.smallcaps}-LC13                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                           50 Gy/25 fr                                                                                                                                                                                                                                                                                                                                                                                                                         

  Sundstrøm *et al.*, 2006 [@b35-co16-2-16]                            Randomized                        To examine the predictive value of baseline [hr qol]{.smallcaps} data in patients receiving [xrt]{.smallcaps} in comparison with demographic, clinical, and treatment variables   A: 17 Gy/2 fr\                                                                                                          301         A: 9.2 Months\                [eortc qlq]{.smallcaps}-C30\                                                                       [kps]{.smallcaps}                       None                                                                                                                   2
                                                                                                                                                                                                                                                                                           B: 42 Gy/15 fr\                                                                                                                     B: 7.5 Months\                [eortc qlq]{.smallcaps}-LC13                                                                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                           C: 50 Gy/25 fr                                                                                                                      C: 7.5 Months                                                                                                                                                                                                                                                                                   

  Temel *et al* ., 2007 [@b36-co16-2-16]                               Prospective                       To assess the feasibility of early palliative care in patients with newly diagnosed [nsclc]{.smallcaps}                                                                           Not stated                                                                                                              51          9.0 Months                    [fact]{.smallcaps}-G\                                                                              [ecog]{.smallcaps}                      [hads]{.smallcaps}                                                                                                     2
                                                                                                                                                                                                                                                                                                                                                                                                                                                             [fact]{.smallcaps}-L                                                                                                                                                                                                                                              
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pts = patients; [qol]{.smallcaps} = quality of life; [rct]{.smallcaps} = randomized clinical trial; [xrt]{.smallcaps} = external-beam radiotherapy; [kps]{.smallcaps} = Karnofsky performance status; fr = fractions; [who]{.smallcaps} = World Health Organization; [mrc]{.smallcaps} = Medical Research Council; [eortc]{.smallcaps} = European Organization for Research and Treatment of Cancer; [ecog]{.smallcaps} = Eastern Cooperative Oncology Group; [hads]{.smallcaps} = Hospital Anxiety and Depression Scale; [rscl]{.smallcaps} = Rotterdam symptom checklist; [swog]{.smallcaps} = Southwest Oncology Group; [lcss]{.smallcaps} = Lung Cancer Symptom Scale; [rt]{.smallcaps} = radiotherapy; [qald]{.smallcaps} = quality-adjusted life-day; [hr]{.smallcaps} = health-related.

###### 

Patients with symptomatic lung cancer treated with endobronchial brachytherapy ([ebb]{.smallcaps}) as compared with external-beam radiotherapy ([xrt]{.smallcaps}) with or without [ebb]{.smallcaps}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                   Type                Study Purpose                                                                                                                                                                                      Arms                                                                                    Pts (*n*)   Median survival   [qol]{.smallcaps}              Assessment tools Performance   Other (*n*)                                                                                                                                Measures of [qol]{.smallcaps}
  ------------------------------------------- ------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------- ----------------- ------------------------------ ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------
  Stout *et al.*, 2000 [@b37-co16-2-16]       [rct]{.smallcaps}   To compare [ebb]{.smallcaps} and [xrt]{.smallcaps} for symptom palliation and the effect on functional status and [qol]{.smallcaps} of patients                                                    A: 30 Gy/8 fr [xrt]{.smallcaps}\                                                        99          A: 287 days\      None                           [who]{.smallcaps}              Study designed: 4-point scoring system to monitor performance status and 9 key symptoms [hads rscl]{.smallcaps} modified for lung cancer   2
                                                                                                                                                                                                                                                                     B: 15 Gy/1 fr [ebb]{.smallcaps}                                                                     B: 250 days                                                                                                                                                                                                                

  Langendijk *et al.*, 2001[@b38-co16-2-16]   [rct]{.smallcaps}   To test that the addition of [ebb]{.smallcaps} to [xrt]{.smallcaps} provides higher levels of palliation of dyspnea and increases [qol]{.smallcaps}                                                A: [xrt]{.smallcaps} alone: 60 Gy/24 fr or 30 Gy/10 fr\                                 95          A: 8.5 months\    [eortc qlq]{.smallcaps}-C30\   [who]{.smallcaps}              None                                                                                                                                       2
                                                                                                                                                                                                                                                                     B: [xrt]{.smallcaps} (60 Gy/24 fr or 30 Gy/10 fr) plus [ebb]{.smallcaps} (15 Gy/2 fr)               B: 7.0 months     [eortc qlq]{.smallcaps}-LC13                                                                                                                                                                             

  Mallick *et al.*, 2006 [@b39-co16-2-16]     Prospective         To test the hypothesis that palliative [ebb]{.smallcaps} treatment with or without [xrt]{.smallcaps} can reduce endobronchial symptoms for a prolonged period and also improve [qol]{.smallcaps}   A: 30 Gy/10 fr with [ebb]{.smallcaps} on days 6 and 13: 8Gy/1fr\                        95          A: 10 months\     [eortc qlq]{.smallcaps}-C30\   [kps]{.smallcaps}              None                                                                                                                                       2
                                                                                                                                                                                                                                                                     B: 30 Gy/10 fr with [ebb]{.smallcaps} on day 13: 10 Gy/1 fr\                                        B: 10 months\     [eortc qlq]{.smallcaps}-LC13                                                                                                                                                                             
                                                                                                                                                                                                                                                                     C: [ebb]{.smallcaps} 15 Gy/1 fr                                                                     C: 10 months                                                                                                                                                                                                               

  Mallick *et al.*, 2007 [@b40-co16-2-16]     Prospective         To compare the subjective and objective responses to 3 regimens for duration, [qol]{.smallcaps} outcomes, and complications                                                                        A: 30 Gy/10 fr with [ebb]{.smallcaps} on days 6 and 13: 8 Gy/1 fr\                      45          Not stated        [eortc qlq]{.smallcaps}-C30\   [kps]{.smallcaps}              None                                                                                                                                       2
                                                                                                                                                                                                                                                                     B: 30 Gy/10 fr with [ebb]{.smallcaps} on day 13: 10 Gy/1 fr\                                                          [eortc qlq]{.smallcaps}-LC13                                                                                                                                                                             
                                                                                                                                                                                                                                                                     C: [ebb]{.smallcaps} 15 Gy/1 fr                                                                                                                                                                                                                                                                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pts = patients; [qol]{.smallcaps} = quality of life; [rct]{.smallcaps} = randomized clinical trial; fr = fractions; [who]{.smallcaps} = World Health Organization; [hads]{.smallcaps} = Hospital Anxiety and Depression Scale; [rscl]{.smallcaps} = Rotterdam symptom checklist; [eortc]{.smallcaps} = European Organization for Research and Treatment of Cancer; [kps]{.smallcaps} = Karnofsky performance status.

###### 

Patients with inoperable lung cancer \[other than non-small-cell lung cancer ([nsclc]{.smallcaps})\] treated with palliative radiotherapy

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                              Type                              Study Purpose                                                                                                                                                                                    Arms                                                                                                                      Pts (*n*)                   Median survival   [qol]{.smallcaps}                   Assessment tools Performance                         Other                                                                                       Measures of [qol]{.smallcaps} (*n*)
  ------------------------------------------------------ --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------- --------------------------- ----------------- ----------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------- -------------------------------------
  Berry *et al.*, 1977[@b41-co16-2-16]                   Prospective                       Compares [xrt]{.smallcaps} alone and with chemotherapy                                                                                                                                           A: 40 Gy/20 fr or 36 Gy/12 fr\                                                                                            A: 48\                      125 Days          None                                None                                                 Study designed: physicians recorded changes in patient symptoms                             0
                                                                                                                                                                                                                                                                                            B: Single-agent continuous chemotherapy\                                                                                  B: 49\                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                            C: Intermittent quadruple chemotherapy                                                                                    C: 51                                                                                                                                                                                                                              

  Collins *et al.*, 1988 [@b42-co16-2-16]                Prospective                       To determine whether palliative [rt]{.smallcaps} should be given to a patient with inoperable carcinoma of the bronchus                                                                          Range: 18 Gy/5 fr--48 Gy/10 fr (split course)                                                                             96                          38 Weeks          None                                [who]{.smallcaps}                                    Study designed: symptom response questions                                                  0

  MRC Lung Cancer Working Party, 1989 [@b43-co16-2-16]   [rct]{.smallcaps} (multicentre)   To compare two policies of treatment                                                                                                                                                             A: Combination chemotherapy and [xrt]{.smallcaps} (40 Gy/15 fr)\                                                          151                         A: 32 weeks\      None                                [who]{.smallcaps}                                    Study designed: treatment reports and daily diary chart                                     0
                                                                                                                                                                                                                                                                                            B: selective treatment: chemotherapy with or without [xrt]{.smallcaps}; treatment given as required to control symptoms                               B: 16 weeks                                                                                                                                                                                            

  Devereux *et al.*, 1997 [@b44-co16-2-16]               Prospective                       To assess the incidence and severity of the immediate side effects of palliative [rt]{.smallcaps} for bronchial carcinoma                                                                        Range: 8 Gy/1 fr--60 Gy/30 fr                                                                                             118                         Not stated        None                                None                                                 Study designed: questionnaire to determine occurrence of symptoms 24 hours post treatment   0

  Rees *et al.*, 1997 [@b45-co16-2-16]                   Randomized prospective            To compare the symptomatic effects of two regimens of [xrt]{.smallcaps}                                                                                                                          A: 17 Gy/2 fr\                                                                                                            A: 111\                     Not stated        None                                [who]{.smallcaps}                                    Study designed: questionnaire to rate severity of symptoms                                  0
                                                                                                                                                                                                                                                                                            B: 22.5 Gy/5fr                                                                                                            B: 105                                                                                                                                                                                                                             

  Ampil *et al.*, 2001[@b46-co16-2-16]                                                     To see the effects of palliative [xrt]{.smallcaps} on patients with synchronous bilateral lung cancers                                                                                           Range: 5--58 Gy (mean dose: 35 Gy)                                                                                        32                          7 Months          None                                [swog]{.smallcaps}                                   Study designed: subjective response                                                         0

  Erridge *et al.*, 2005 [@b47-co16-2-16]                [rct]{.smallcaps}                 To determine whether palliation of chest symptoms was the same in two fractionation schedules                                                                                                    A: 10 Gy/1 fr\                                                                                                            149                         A: 28.3 Weeks\    Spitzer's [qol]{.smallcaps} Index   [who]{.smallcaps}                                    [hads]{.smallcaps}\                                                                         1
                                                                                                                                                                                                                                                                                            B: 30 Gy/10 fr                                                                                                                                        B: 22.7 Weeks                                                                                              [ecog]{.smallcaps}                                                                          

  Turner *et al.*, 2005 [@b48-co16-2-16]                 Prospective                       To see if older people benefit from [xrt]{.smallcaps} treatment, both in control of symptoms and improvement in [qol]{.smallcaps} ([nsclc]{.smallcaps}, [sclc]{.smallcaps}, and unknown types)   A: "High dose": (36/39 Gy in 12/13 fr)\                                                                                   Elderly (\>75 years): 83\   A: 9 months\      [eortc qlq]{.smallcaps}-C30\        [who]{.smallcaps}, Barthel [adl]{.smallcaps} Scale   [hads]{.smallcaps} Concerns Checklist                                                       2
                                                                                                                                                                                                                                                                                            B: ''low dose'': (10 Gy in 1 fr, 17 Gy in 2 fr or 20 Gy in 5 fr)                                                          Younger (\<65 years): 49    B: 7 months       [eortc qlq]{.smallcaps}-LC17                                                                                                                                                         

  Hicsönmez *et al.*, 2007 [@b49-co16-2-16]                                                Evaluate efficacy of palliative [xrt]{.smallcaps} in terms of [qol]{.smallcaps} and how [ecog]{.smallcaps} correlates with [eortc qlq]{.smallcaps}-C30                                           Not stated                                                                                                                88                          Not stated        [eortc qlq]{.smallcaps}-C30         [ecog]{.smallcaps}                                   None                                                                                        1
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Pts = patients; [qol]{.smallcaps} = quality of life; [xrt]{.smallcaps} = external-beam radiotherapy; fr = fractions; [rt]{.smallcaps} = radiotherapy; [who]{.smallcaps} = World Health Organization; [mrc]{.smallcaps} = Medical Research Council; [rct]{.smallcaps} = randomized clinical trial; [swog]{.smallcaps} = Southwest Oncology Group; [hads]{.smallcaps} = Hospital Anxiety and Depression Scale; [ecog]{.smallcaps} = Eastern Cooperative Oncology Group; [sclc]{.smallcaps} = small-cell lung cancer; [eortc]{.smallcaps} = European Organization for Research and Treatment of Cancer.

###### 

Frequency of instruments used in clinical trials measuring quality of life ([qol]{.smallcaps}) in patients with locally advanced lung cancer or lung metastases

  Instrument                                                                         Frequency
  ---------------------------------------------------------------------------------- -----------
  European Organization for Research and Treatment of Cancer ([eortc]{.smallcaps})   
   General cancer questionnaire ([eortc qlq]{.smallcaps}-C30)                        13
   Lung cancer questionnaire ([eortc qlq]{.smallcaps}-LC13)                          7
   Lung cancer questionnaire ([eortc qlq]{.smallcaps}-LC17)                          1
  Functional Assessment of Cancer Therapy ([fact]{.smallcaps})                       
   General questionnaire ([fact]{.smallcaps}-G)                                      1
   Lung questionnaire ([fact]{.smallcaps}-L)                                         2
  Spitzer [qlq]{.smallcaps} Index                                                    1
  Hospital Anxiety and Depression Scale ([hads]{.smallcaps})                         5
  Rotterdam Symptom Checklist ([rscl]{.smallcaps})                                   4
  Study-designed [qlq]{.smallcaps} questionnaire                                     3
  Lung Cancer Symptom Scale ([lcss]{.smallcaps})                                     2
  Study-designed symptom palliation questionnaire                                    19

###### 

Use of validated or study-designed tools in forty-three studies

                   Questionnaire type[a](#tfn4-co16-2-16){ref-type="table-fn"}             
  ---------------- ------------------------------------------------------------- ---- ---- ----
  Validated        9                                                             21   16   37
  Study-designed   21                                                            49   3    7
  Total            30                                                            70   19   44

Six studies used both a [qol]{.smallcaps} and a symptom palliation tool.
